Zollinger-Ellison syndrome: Difference between revisions
No edit summary |
Erdojjones (talk | contribs) |
||
| Line 22: | Line 22: | ||
==Management== | ==Management== | ||
*Proton-Pump Inhibitors | |||
*Somatostatin analog (Octreotide) if no improvement | |||
**Direct inhibition of gastric secretion | |||
*Surgical resection | |||
==Disposition== | ==Disposition== | ||
Revision as of 23:29, 1 November 2022
Background
- Also known as "S-E syndrome"
- gastric neuroendocrine malignancy results in hypersecretion of hydrochloric acid by parietal cells
- Associated with peptic ulcers and diarrhea
- 60% malignant, only 20% resectable; 25% of gastrinoma patients have multiple endocrine neoplasia type I; >80% of gastrinomas found in gastrinoma triangle.
Clinical Features
- Hematemesis
- Chronic diarrhea
- Postprandial abdominal pain
- Nausea
- Wheezes on auscultation
- Evidence of malnourishment and decreased oral intake
Differential Diagnosis
Evaluation
Workup
Diagnosis
Management
- Proton-Pump Inhibitors
- Somatostatin analog (Octreotide) if no improvement
- Direct inhibition of gastric secretion
- Surgical resection